Rise Therapeutics LLC
Rockville, MD
- UEI
- N36JMJ1DKWH6
- CAGE
- 7U7H1
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Partnership or Limited Liability Partnership
- SAM.gov registration date
- Physical address
- 1405 Research Blvd #220, Rockville, MD 20850, USA
- Website
- risetherapeutics.com
- Employees
- 1-10
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
About the company
Rise Therapeutics LLC, a small biotechnology company headquartered in Rockville, Maryland, is a federal grant recipient developing engineered live biotherapeutic products and microbiome-based therapeutics for autoimmune and inflammatory diseases, operating exclusively as a prime recipient across the National Institutes of Health (100% of recent awards).
Rise's customer concentration is highly concentrated within NIH. The top five NIH institutes account for 95% of recent awards, led by the National Institute of Diabetes and Digestive and Kidney Diseases (seven awards, including the most recent grant), followed by the National Institute of Allergy and Infectious Diseases (six awards), the National Institute of Dental and Craniofacial Research (four awards), the National Cancer Institute (one award), and the National Center for Advancing Translational Sciences (one award). All twenty tracked awards are project grants or cooperative agreements, not contracts.
Rise's core capability is the development of recombinant Lactococcus lactis probiotics engineered to express immunomodulatory proteins and targeted therapeutic payloads. Recent representative grants include a $1,042,478 award from NIDDK (awarded September 1, 2026, running through August 31, 2028) to evaluate safety and clinical efficacy of R-3750, an engineered live biotherapeutic designed to modulate intestinal immune responses and restore gut homeostasis in Crohn's disease patients, building on a Phase 1 safety profile in an ongoing ulcerative colitis trial; a $429,158 cooperative agreement from the National Institute of Dental and Craniofacial Research (awarded August 14, 2025, running through August 13, 2026) to develop a novel immunologically-directed L. lactis probiotic for Sjogren's syndrome treatment; and a project grant from NIDDK (awarded July 5, 2022, running through July 31, 2027) focused on an engineered live biotherapeutic product leveraging surface layer protein expression to inhibit gut inflammatory processes in inflammatory bowel disease. Rise also holds grants targeting Type 1 diabetes, rheumatoid arthritis, multiple sclerosis, and viral-induced acute respiratory distress syndrome, all leveraging probiotic-based immunomodulation via recombinant bacterial strains.
Activity has declined year over year — three awards in 2022 to one in 2024 — though two awards were added in 2025 and one in 2026. Six awards face ultimate completion inside the next twenty-four months, representing near-term recompete opportunity. Rise maintains in-house GMP manufacturing infrastructure for its recombinant probiotic platforms and has demonstrated proof-of-concept across more than fifteen animal models for its Lactococcus lactis delivery approach. Work is performed at the company's Rockville, Maryland facility.
Quick answers
Is Rise Therapeutics LLC registered in SAM.gov?
Yes. Rise Therapeutics LLC's SAM.gov registration is active through December 25, 2026.
What is Rise Therapeutics LLC's CAGE code?
Rise Therapeutics LLC's CAGE code is 7U7H1, and its Unique Entity ID (UEI) is N36JMJ1DKWH6.
What is Rise Therapeutics LLC's most recent federal award?
Rise Therapeutics LLC's most recent federal grant award is A novel immunological-directed live biotherapy product for treating crohn's disease (R44DK146369), from National Institute of Diabetes and Digestive and Kidney Diseases (NIH), on September 1, 2026.
On GovTribe
See Rise Therapeutics LLC's full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors